Literature DB >> 6803246

Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody.

C A Fulcher, T S Zimmerman.   

Abstract

The human factor VIII procoagulant protein (VIIIC) was purified from the VIIIC--factor VIII--related antigen (VIIIRAg) complex in commercial factor VIII concentrate by immunoadsorbent chromatography with a monoclonal anti-VIIIRAg antibody bound to Sepharose. In this complex, VIIIC is noncovalently bound to factor VIII-related antigen. The VIIIC eluted from the complex was free of VIIIRAg as determined by immunoassay and had a specific activity of 2,294 VIIIC units/mg of protein, representing a 164,000-fold purification from plasma. Electrophoresis of this VIIIC preparation in reduced sodium dodecyl sulfate containing 5% polyacrylamide slab gels and subsequent staining with Coomassie blue showed the VIIIC to be a strongly staining doublet of Mrs 79,000 and 80,000 and more faintly staining bands of up to Mr 188,000. Treatment of the VIIIC with catalytic amounts of thrombin resulted in diminution or complete disappearance of all of these bands and appearance of a doublet of Mrs 71,000 and 72,000, a band at Mr 54,000, and material of lower Mr. The purified VIIIC was used to produce a precipitating heterologous anti-VIIIC antibody, which was shown to be monospecific for VIIIC after adsorption with factor VIII-depleted commercial concentrate. Use of this antibody in crossed immunoelectrophoresis positively identified the VIIIC bands in the sodium dodecyl sulfate/polyacrylamide gels. These techniques have allowed the identification of VIIIC protein and description of its extensive Mr heterogeneity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6803246      PMCID: PMC346033          DOI: 10.1073/pnas.79.5.1648

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  Letter: A more uniform measurement of factor VIII inhibitors.

Authors: 
Journal:  Thromb Diath Haemorrh       Date:  1975-12-15

Review 2.  Antibodies to blood coagulation factors.

Authors:  S S Shapiro
Journal:  Clin Haematol       Date:  1979-02

3.  The properties of factor VIII coagulant activity prepared by immunoadsorbent chromatography.

Authors:  E G Tuddenham; N C Trabold; J A Collins; L W Hoyer
Journal:  J Lab Clin Med       Date:  1979-01

4.  Elimination of nonspecific adsorption of serum proteins by Sepharose-bound antigens.

Authors:  J A Smith; J G Hurrell; S J Leach
Journal:  Anal Biochem       Date:  1978-07-01       Impact factor: 3.365

5.  Electrophoretic analysis of the major polypeptides of the human erythrocyte membrane.

Authors:  G Fairbanks; T L Steck; D F Wallach
Journal:  Biochemistry       Date:  1971-06-22       Impact factor: 3.162

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  The chromatographic separation of factor VIII on aminohexyl sepharose.

Authors:  D E Austen
Journal:  Br J Haematol       Date:  1979-12       Impact factor: 6.998

8.  Visualization of low molecular weight factor VIII purified in the presence of benzamidine.

Authors:  E P Kang; W H Cruickshank; G Rock
Journal:  Thromb Res       Date:  1980 Feb 1-15       Impact factor: 3.944

9.  Protein antigens of normal and malignant human cells identified by immunoprecipitation with monoclonal antibodies.

Authors:  J P Brown; P W Wright; C E Hart; R G Woodbury; K E Hellström; I Hellström
Journal:  J Biol Chem       Date:  1980-06-10       Impact factor: 5.157

10.  Preparation and properties of bovine factor VIII (antihemophilic factor).

Authors:  G A Vehar; E W Davie
Journal:  Biochemistry       Date:  1980-02-05       Impact factor: 3.162

View more
  22 in total

Review 1.  Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.

Authors:  R J Kaufman
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

2.  Product-dependent anti-factor VIII antibodies.

Authors:  S Butenas; J Krudysz-Amblo; G E Rivard; K G Mann
Journal:  Haemophilia       Date:  2013-04-04       Impact factor: 4.287

3.  Localization of a factor VIII-inhibiting antibody epitope to a region between residues 338 and 362 of factor VIII heavy chain.

Authors:  J Ware; J R Toomey; D W Stafford
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

4.  Structural model of porcine factor VIII and factor VIIIa molecules based on scanning transmission electron microscope (STEM) images and STEM mass analysis.

Authors:  M W Mosesson; D N Fass; P Lollar; J P DiOrio; C G Parker; G J Knutson; J F Hainfeld; J S Wall
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

5.  Isolation and characterization of human factor VIII: molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma.

Authors:  L O Andersson; N Forsman; K Huang; K Larsen; A Lundin; B Pavlu; H Sandberg; K Sewerin; J Smart
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

6.  Production and Purification of Rabbit's Polyclonal Antibody Against Factor VIII.

Authors:  Simin Sohrabi; Azim Akbarzadeh; Dariush Norouzian; Ali Farhangi; Mehri Mortazavi; Mohammad Reza Mehrabi; Mohsen Chiani; Zahra Saffari; Soheil Ghassemi
Journal:  Indian J Clin Biochem       Date:  2011-06-08

7.  Two distinct forms of Factor VIII coagulant protein in human plasma. Cleavage by thrombin, and differences in coagulant activity and association with von Willebrand factor.

Authors:  M J Weinstein; L E Chute
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

8.  Potency and mass of factor VIII in FVIII products.

Authors:  S Butenas; B Parhami-Seren; M T Gissel; E D Gomperts; D N Fass; K G Mann
Journal:  Haemophilia       Date:  2008-08-06       Impact factor: 4.287

9.  Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit.

Authors:  J A Dent; M Galbusera; Z M Ruggeri
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

10.  Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments.

Authors:  C A Fulcher; S de Graaf Mahoney; J R Roberts; C K Kasper; T S Zimmerman
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.